Everest Medicines Acquires Asia Commercial Platform for $250 Million
Event summary
- Everest Medicines is acquiring Hasten Biopharmaceuticals (SG) Pte. Ltd. for a total consideration of USD 250 million, payable in three installments.
- The acquisition includes 14 marketed chronic disease products with 2025 normalized revenue of USD 82.2 million and EBITDA of USD 27.3 million.
- The first installment of USD 150 million will be paid at closing, with subsequent installments due in Q1 2028 and Q1 2029, contingent on certain conditions.
- Hasten Biopharmaceuticals (SG) Pte. Ltd. has a commercial team of approximately 120 field forces across the Asia Pacific region.
The big picture
Everest Medicines is strategically positioning itself to capitalize on the growing demand for innovative medicines in the Asia Pacific region, particularly as Chinese pharmaceutical innovation gains traction. The acquisition provides an immediate commercial footprint and a portfolio of chronic disease products, accelerating Everest’s regional expansion beyond its established presence in China. This $250 million deal underscores the increasing attractiveness of the Asia Pacific market for biopharmaceutical companies seeking growth opportunities.
What we're watching
- Integration Risk
- The success of this acquisition hinges on Everest Medicines’ ability to effectively integrate Hasten Biopharmaceuticals (SG) Pte. Ltd.’s commercial operations and field force, which could be complicated by cultural differences and operational inconsistencies.
- Regulatory Landscape
- The accelerated adoption of Chinese medicines in the Asia Pacific region is predicated on continued favorable regulatory changes and market access frameworks, which could be subject to political or economic shifts.
- Payment Schedule
- The deferred payment structure introduces a risk if Hasten Biopharmaceuticals (SG) Pte. Ltd. fails to meet performance targets, potentially triggering a re-evaluation of the acquisition’s value and Everest’s financial obligations.
Related topics